Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations

Advanced Drug Delivery Reviews

Volumn 54, Issue 2, 2002, Pages 191-202

  Liggins, R T ^a   Burt, H M ^b  

^a Angiotech Pharmaceuticals Inc   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Micelles; Paclitaxel; Poly(D,L lactide) b methoxypolyethylene glycol

Indexed keywords

COPOLYMERS; MICELLES; POLYESTERS; POLYMERIZATION; SYNTHESIS (CHEMICAL);

PACLITAXEL;

DRUG DOSAGE;

CHEMICAL COMPOUND; COPOLYMER; CREMOPHOR; DOCETAXEL; MACROGOL; METHOXYPOLYETHYLENE GLYCOL BLOCK POLY(DEXTRO,LEVO LACTIDE); MONOMER; PACLITAXEL; POLYESTER; POLYETHER; POLYMER; POLYSORBATE 80; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTHRITIS; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONCENTRATION (PARAMETERS); DISEASE MODEL; DISSOLUTION; DOG; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SOLUBILITY; HEAT; HYDROPHOBICITY; LUNG TUMOR; METHODOLOGY; MICELLE; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RADIATION; SOLUBILIZATION; SYNTHESIS; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHYSICAL; DRUG DELIVERY SYSTEMS; HUMANS; MICELLES; PACLITAXEL; POLYESTERS; POLYMERS; TISSUE DISTRIBUTION;

EID: 0037148660     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00016-9     Document Type: Article

References (67)

1. Safety profile
2. Hypersensitivity reactions from taxol
3. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel
4. Overview of taxol safety
5. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
6. Paclitaxel hypersensitivity revisited
7. Effects of cyclosporine on the ioslated perfused rat kidney
8. In vitro and in vivo anti-tumoral activity of free and encapsulated taxol
9. Polymeric micelle-like aggregates as systems to solubilize and delivery paclitaxel to cancer cells: In vitro study
10. Novel Taxol® formulation: Polyvinylpyrrolidone nanoparticle-encapsulated Taxol® for drug delivery in cancer therapy
11. Interaction of taxol and other anti-cancer drugs with alpha-cyclodextrin
12. In vitro modulation of doxorubicin and docetaxel anti-tumoral activity by methyl-beta-cyclodextrin
13. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins
14. Solubility and stability of taxol: Effects of buffers and cyclodextrins
15. A new parenteral emulsion for the administration of taxol
16. Novel therapeutic nano-particles (lipocores): Trapping poorly water soluble compounds
17. Synthesis and evaluation of water soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug
18. Role of formulation vehicles in taxane pharmacology
19. Development of novel chitosan derivatives as micellar carriers of taxol
20. Development of amphiphilic diblock copolymers as micellar carriers of taxol
21. Biodegradable long-circulating polymeric nanospheres
22. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres
23. Novel PDLLA/PEG copolymer micelles as drug carriers
24. Preparation and characterization of biodegradable nanospheres composed of methoxy poly(ethylene glycol) and D,L-lactide block copolymer as novel drug carriers
25. Drug releasing characteristics of PDLLA-MPEG Di and MPEG-PDLLA-MPEG triblock copolymer micelles
26. Polycaprolactone-b-polyethylene oxide copolymer micelles as a delivery vehicle for dihydrotestosterone
27. Paclitaxel delivery via polymeric micelles: In vivo studies
28. Diblock copolymer nanoparticles for drug delivery
29. Polymeric micelles - A new generation of colloidal drug carriers
30. Structure and design of polymeric surfactant-based drug delivery systems
31. Biodegradable polymers for use in surgery - Poly(glycolic)/poly(lactic acid) homo and copolymers: 2. In vitro degradation
32. Development of copolymers of poly(D,L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel
33. Polylactide-poly(ethylene glycol) copolymers as drug delivery systems. 1. Characterization of water dispersible micelle-forming systems
34. Effect of preparative variables on the properties of poly(D,L-lactide-co-glycolide)-methoxypoly (ethyleneglycol) copolymers related to their application in controlled drug delivery
35. Thermal characterization of polylactides
36. Aliphatic polyesters. III. Molecular weight and molecular weight distribution in alcohol-initiated polymerization of e-caprolactone
37. Amphiphilic diblock copolymeric nanospheres composed of methoxy poly(ethylene glycol) and glycolide: Properties, cytotoxicity and drug release behaviour
38. Methoxy poly(ethylene glycol)/e-caprolactone amphiphilic block copolymeric micelle containing indomethacin. I. Preparation and characterization
39. Methoxy poly(ethylene glycol)/e-caprolactone amphiphilic block copolymeric micelle containing indomethacin. I. Micelle formation and drug release behaviours
40. Poly-D,L-lactic acid: Polyethylene glycol block copolymers. The influence of polyethylene glycol on the degradation of poly-D,L-lactic acid
41. Paclitaxel loaded poly(L-lactic acid) microspheres: Properties of microspheres made with low molecular weight polymers
42. Biodegradable block copolymers as injectable drug-delivery systems
43. Polymeric micelles as drug delivery systems: A reactive polymeric micelle carrying aldehyde groups
44. Sugar-installed polymer micelles synthesis and micellization of poly(ethylene glycol)-poly(D,L-lactide) block copolymers having sugar groups at the PEG chain end
45. Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles
46. 'Super microcapsules' (SMC). I. Preparation and characterization of star polyethylene oxide (PEO)-polylactide (PLA) copolymers
47. Erosion of biodegradable block copolymers made of poly(D,L-lactic acid) and polyethylene glycol
48. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier
49. A DSC study of the miscibility of poly(ethylene oxide)-block-poly(D,L-lactide) copolymers with poly(D,L-lactide)
50. Core-stabilized polymer micelle as potential drug carrier: Increased solubilization of taxol
51. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy
52. Physical characterization of paclitaxel
53. An investigation of the anti-tumor activity and biodistribution of polymeric micellar paclitaxel
54. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel
55. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate
56. Micellar taxol and methotrexate in collagen-induced arthritis: Suppression of synovial angiogenesis and regression of arthritis
57. Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel
58. Taxol involution of collagen-induced arthritis: Ultrastructural correlation with the inhibition of synovitis and neovascularization
59. Regression of collagen-induced arthritis with taxol, a microtubule stabilizer
60. Myelin in multiple sclerosis is developmentally immature
61. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocyte system
62. Methoxypolyethylene glycol/D,L-lactide amphiphlic block copolymeric micelle containing paclitaxel (Genexol): Toxicity and efficacy